A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Status:
Recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4（CDK4）and
CDK6 kinase activity. The purpose of this study is to evaluate the safety, efficacy and
pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects
with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2
negative (HER2-) breast cancer.